Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
Helus Pharma appointed Dr. Suresh Durgam to its Board of Directors, promoting him from the company's Scientific Advisory Board. Dr. Durgam was EVP and Chief Medical Officer of Intra-Cellular Therapies, where he helped secure FDA approvals for CAPLYTA across schizophrenia, bipolar depression, and adjunctive MDD; Intra-Cellular was acquired by Johnson & Johnson in April 2025.
Key figures
- Hlp003 phase
- Phase 3 (adjunctive MDD, Breakthrough Therapy Designation)
- Hlp004 phase
- Phase 2 (generalized anxiety disorder)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.